Christy Whillock
Family · Fayetteville, ARNPI 1073151742
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $322, 3.1 times the $102 reported in 2021.
Across 49 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$223
- Gilead$123
- Johnson & Johnson$73
- Bayer$71
- Novocure Inc.$65
- Takeda Pharmaceuticals U.S.A., Inc.$51
- plus $409 from 21 others
Across 4 payments — averaging $259.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis Pharma AG$1K
What the payments were for
- Food & beverage$1,014100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 8 | $223 |
| Gilead | 1 | $123 |
| Johnson & Johnson | 5 | $73 |
| Bayer | 1 | $71 |
| Novocure Inc. | 2 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $51 |
| Eisai Inc. | 3 | $40 |
| Sanofi | 3 | $37 |
| Merck | 2 | $31 |
| Genmab U.S., Inc. | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 2 | $26 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $25 |
| Bristol Myers Squibb | 1 | $23 |
| AbbVie | 1 | $20 |
| Genentech USA, Inc. | 1 | $18 |
| EMD Serono, Inc. | 1 | $17 |
| AstraZeneca | 1 | $14 |
| Pharmaessentia USA Corporation | 1 | $14 |
| Sobi, Inc | 1 | $14 |
| Morphosys, US Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $13 |
| Exelixis Inc. | 1 | $13 |
| Servier Pharmaceuticals LLC | 1 | $13 |
| Heron Therapeutics, Inc. | 1 | $12 |
| Tersera Therapeutics LLC | 1 | $12 |
| Kyowa Kirin, Inc. | 1 | $12 |
| Rigel Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,014 in reported general payments places this provider in the 65th percentile of 2,103 family providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 34 | $477 |
Paid to pharmacies, not to this prescriber.
Other family in Fayetteville
- Shelby CochranFayetteville$23K
- Margaret OliverFayetteville$12K
- Christopher TitsworthFayetteville$9K
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.